Galapagos (NASDAQ:GLPG) was downgraded by stock analysts at BidaskClub from a “sell” rating to a “strong sell” rating in a report released on Saturday.
Several other equities research analysts have also weighed in on the company. ValuEngine lowered Galapagos from a “hold” rating to a “sell” rating in a report on Friday. BTIG Research reissued a “buy” rating and issued a $118.00 price objective on shares of Galapagos in a report on Monday, November 20th. Stifel Nicolaus reissued a “buy” rating and issued a $120.00 price objective on shares of Galapagos in a report on Sunday, October 29th. Zacks Investment Research raised Galapagos from a “sell” rating to a “hold” rating in a report on Wednesday, October 11th. Finally, Morgan Stanley reissued an “overweight” rating and issued a $123.00 price objective (up previously from $92.00) on shares of Galapagos in a report on Friday, October 6th. Two analysts have rated the stock with a sell rating, three have assigned a hold rating and six have issued a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and a consensus target price of $111.00.
Shares of Galapagos (GLPG) traded down $0.93 on Friday, reaching $87.25. The company had a trading volume of 86,505 shares, compared to its average volume of 76,725. Galapagos has a 52 week low of $57.86 and a 52 week high of $104.12.
WARNING: This report was published by American Banking News and is owned by of American Banking News. If you are reading this report on another domain, it was illegally copied and reposted in violation of U.S. and international copyright and trademark law. The legal version of this report can be read at https://www.americanbankingnews.com/2017/12/02/galapagos-glpg-downgraded-by-bidaskclub-to-strong-sell.html.
Galapagos NV is a Belgium-based biotechnology company. The Company’s activities are divided into two operating divisions: Research and Development (R & D) and Services. The R & D division is engaged in the discovery and development of small molecules. The Services division, offers target-to-drug discovery products and services to pharmaceutical and biotechnology companies and to patient foundations, encompassing target discovery and validation, screening and drug discovery through to delivery of pre-clinical candidates.
Receive News & Ratings for Galapagos NV Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galapagos NV and related companies with MarketBeat.com's FREE daily email newsletter.